ArticleBlood cancer journal2021

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML.

Xinan Qiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.